Studies » Ongoing Studies Mammacarcinom

Ongoing Studies Mamma
Carcinom

Study 12

Studies
No.		 Studies Title Studies Design Coordinating Invesitgator Random sample Starting of recruitment
ABCSG 34
34
 Neoadjuvant chemotherapy* +/- Sunitinib before surgery for the treatment of patients with operable breast cancer.
A multicenter, randomized, double-blind, placebo-controlled, phase III clinical trial 		ABCSG 34
ABCSG 34
Study 34
 Gnant, M. 520  

31
 A randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer
Studie 31
Study 31
 Gnant, M. international 8.000,
Austria 150		 in Austria 21.04.2009

29
 A randomized, multicenter, open phase III studycomparing the postoperative use ofzoledronic acid versus no treatmentin patients with histological tumor residuals afterpreoperative anthracycline and taxane containingchemotherapy for primary breast cancer
Study 29
 Dubsky, P. total 654 in Austria
12.08.2008

30
 A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab
Study 30
Study 30
 Steger, G. 3.500 in Austria 12.09.2008

27
 An international multi-centre open-label 2-arm phase III trial of adjuvant bevacizumab in triple negative breast cancer.
Study 27
 Steger, G 2.530 (1.265 each arm) 11/2007

25
 A randomized phase III study comparing biweekly and tailored epirubicin and cyclophosphamide followed by biweekly tailored docetaxel (dtEC dtT) (A-arm) versus three weekly epirubicin and cyclophosphamide, 5-fluourouracil followed by docetaxel (FEC T) (B-arm) in lymph node positive breast cancer patients or high risk lymph node negative breast cancer patients – a continuation of the feasibility part of the SBG 2004-1 study
Study 25
 Greil, R Austria 450, Total 900 3rd quarter 2007

18
 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase 3 Study to Determine the Treatment Effect of Denosumab in Subjects with Non-Metastatic Breast Cancer Receiving Aromatase Inhibitor Therapy

Detailed information ›
Studie 18
 Gnant, M 2.800 (1.400 je Arm) 11/2006
15
(int.
Ibis II)
 An international multi-centre study of tamoxifen vs anastrozole in postmenopausal women with Ductal Carcinoma in Situ (DCIS).

Detailed information ›
Study 15
Stierer, M
on behalf of the ABCSG 		4.000 (int.) 4th. quarter 2004

16
(Salsa)
S.A.L.S.A. (Secondary Adjuvant Longterm Study with Arimidexâ):
A prospective, randomized, open, multicentre phase III-study to assess the efficacy of secondary adjuvant endocrine therapy with anastrozole for 2 vs. 5 further years in patients with hormone receptor positive breast cancer after a 5-year primary adjuvant endocrine therapy.

Detailed information ›
Study 16
Gnant, M 3.500 12/2003